ZTSZoetis

$77.53

The financials

Zoetis by the numbers

Zoetis (ZTS) reported revenue of $2.47B in Q2 2026 (quarter ended June 30, 2026), down 0.2% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $691M (28% of revenue). For the full year FY2025, revenue was $9.47B (+2.3% year on year) and net income $2.67B. Its largest product in 2026-Q1 was Cattle at $392M, 18% of the disclosed total, just ahead of Dermatology at 16%.

Zoetis income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$2.47B$2.47B−0.2%
Gross profit$1.79B$1.81B−0.8%
Net income$691M$726M−4.8%
Diluted EPS$1.65$1.63+1.2%
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Cattle$392M18%
Dermatology$349M16%
Anti Infective Products$241M11%
Livestock$225M10%
Pain Sedation$203M9.3%
Other Pharmaceuticals$158M7.3%
Swine$123M5.6%
Poultry$118M5.4%
Animal Health Diagnostics$117M5.4%
Horses$76M3.5%
Fish$66M3.0%
Other Non Pharmaceuticals$66M3.0%
Contract Manufacturingand Human Health Diagnostics$23M1.1%
Manufactured Product Other$21M1.0%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $2.18B (-8.6%)
Fish grew +20% year on yearContract Manufacturing and Human Health Diagnostics -23% year on year
  • Cattle$392.0MQoQ -1.8%year on year +15%
  • Dermatology$349.0MQoQ -26%year on year -7.9%
  • Anti Infective Products$241.0MQoQ -15%year on year +1.3%
  • Livestock$225.0MQoQ -11%year on year +7.1%
  • Pain Sedation$203.0MQoQ -0.49%year on year -1.9%
  • Other Pharmaceuticals$158.0MQoQ -11%year on year 0.00%
  • Swine$123.0MQoQ +11%year on year +17%
  • Poultry$118.0MQoQ +11%year on year +11%
  • Animal Health Diagnostics$117.0MQoQ +6.4%year on year +13%
  • Horses$76.0MQoQ +15%year on year +19%
  • Fish$66.0MQoQ -15%year on year +20%
  • Other Non Pharmaceuticals$66.0MQoQ +3.1%year on year -7.0%
  • Contract Manufacturing and Human Health Diagnostics$23.0MQoQ 0.00%year on year -23%
  • Manufactured Product Other$21.0MQoQ -32%year on year +5.0%
  • Medicated Feed Additives-QoQ -year on year -
Segment sum = 96% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-07, SEC EDGAR